The SWOG Statistical and Data Management Center (SDMC) plays a vital role in SWOG's overall mission to direct and participate in clinical trials tht will lead to effective treatment and prevention of cancer and to improve quality of life for cancer patients and survivors. The SDMC provides statistical leadership and data management expertise in the design, implementation, monitoring, analysis and interpretation of clinical trials and translational medicine studies. Key SDMC goals include the following: a) to design and implement statistically rigorous and efficient clinical trials;b) to carefully monitor ongoing trils and use state-of-the-art statistical analysis methods to analyze and interpret study results;c) to conduct statistical methods research in clinical trial design and analysis, and the analysis of translational medicine studies;d) to develop systems and utilize technologies for high quality and timely collection, review, storage and retrieval of clinical and biologic data;e) to educate SWOG investigators and other oncology research professionals in leading edge scientific design, statistical techniques and data management methods;f) to evaluate novel strategies for the efficient collection of specific types of patient data including electronic medical record (EMR and web-based methods;and g) to be a dynamic member of the NCTN by providing a wealth of experience and leadership for NCTN endeavors such as steering committees and working groups. The SWOG SDMC contributes meaningfully to the goals of SWOG within the NCTN to provide generalizable, high quality and efficient strategies that can be used by other clinical trials organizations and researchers in the conduct of oncology clinical trials and analysis of associated biologic studies.

Public Health Relevance

Well designed and conducted clinical trials are the primary means for improving therapy for cancer, advancing the chance for cure and increasing the length and quality of life of patients. The SWOG SDMC aims to be a leader in the field through efficient and high-quality design, management, and analysis of these trials, thereby helping to ensure that the results of clinical trials have the greatest potential impact on cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180819-01
Application #
8605318
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-17
Project End
2019-02-28
Budget Start
2014-04-17
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Herbst, Roy S; Redman, Mary W; Kim, Edward S et al. (2018) Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol 19:101-114
Othus, Megan; Sekeres, Mikkael A; Nand, Sucha et al. (2018) Relative survival following response to 7?+?3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia :
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Statler, Abby; Othus, Megan; Erba, Harry P et al. (2018) Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood 131:2782-2788
Rimsza, Lisa M; Li, Hongli; Braziel, Rita M et al. (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151-e153
Dai, James Y; Liang, C Jason; LeBlanc, Michael et al. (2018) Case-only approach to identifying markers predicting treatment effects on the relative risk scale. Biometrics 74:753-763
Sharma, P; Barlow, W E; Godwin, A K et al. (2018) Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol 29:654-660
Zhan, Xiang; Wu, Michael C (2018) Reader Reaction: A note on testing and estimation in marker-set association study using semiparametric quantile regression kernel machine. Biometrics 74:764-766

Showing the most recent 10 out of 156 publications